Bioxodes
Gosselies, Belgium · Founded 2013 · $6.5M raised
- Headquarters
- Gosselies
- Employees
- 11–50
- Founded
- 2013
- Website
- bioxodes.com
- Total Funding
- $6.5M
- Last Round
- $6.5M Extension RoundDec 2025
- Rounds
- 1
About
Bioxodes is a clinical-stage biotech company developing a pipeline of therapeutics to tackle thrombo-inflammation at its source. Its lead asset, BIOX-101, is a recombinant protein derived from tick saliva with a dual anticoagulant and anti-inflammatory mechanism, currently advancing toward a Phase 2b trial for intracerebral hemorrhage — a deadly form of stroke for which no approved treatment exists. The company is also developing BIOX-101 for ischemic stroke and additional thrombo-inflammatory indications, operating out of the Brussels South Charleroi Biopark in Belgium.
Summary
Bioxodes is a Biotech company based in Gosselies, Belgium, founded in 2013. It has raised $6.5M in total across 1 round, most recently a $6.5M Extension Round round in Dec 2025.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2025
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company